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"~URRENT therapies have done little to improve the poor prognosis of patients with malignant 16 18 19 r glioma. '' Unlike surgery, irradiation, o chemotherapy, which are limited by their effects on normal tissue, immunotherapy can selectively destroy tumor tissue. This has generated interest in immunotherapy as an adjunctive treatment. In 1982, it was first reported that the lymphocytes of cancer patients could be activated in vitro to a tumoricidal state merely by incubation with interleukin-2 (IL-2) alone for a minimum of 2 days. 4 The ability of these lymphokineactivated killer (LAK) cells to lyse nonglial tumors was profound.
Recently, we reported that culture of brain-tumor patients' lymphocytes with recombinant IL-2 results in the generation of LAK cells which produce marked lysis of autologous glioma in vitro. 7 These results prompted the institution of a Phase I study at the National Institutes of Health (NIH) and the report of our initial observations, s We now present follow-up results and previously unpublished neurosurgical aspects of the Phase I trial, in which nine patients were treated with either LAK cells or IL-2. The lack of adverse side effects in these nine patients has allowed us to continue with the potentially therapeutic part of our Phase I study in which LAK cells and IL-2 will be administered simultaneously; one patient has received this combined therapy and has shown no apparent toxicity.
Clinical Material and Methods

Patient Selection
Patients over 18 years of age with histological evidence of malignant glioma were eligible for treatment. Criteria for entry into the study included the following: l) a life expectancy of 6 weeks; 2) recovery from the toxic effects of all prior chemotherapy or radiotherapy; 3) a Karnovsky rating over 50; 4) adequate hematological status, with a white blood cell (WBC) count greater than or equal to 4000/cu mm and a platelet count greater than or equal to 100,000/cu mm; and 5) a tumor of sufficient size, as determined by computerized tomography (CT), to warrant surgical debulking. Patients who had received irradiation or chemotherapy in the preceding 4 weeks or surgery in the previous 6 months were excluded from the study. All patients had progressive disease documented by clinical examination and CT, and all gave informed consent. 28, F 1: eraniotomy for tumor removal 1 x 10 j~ 6 mos 2: whole-brain radiation (6500 rads) 10 50, M 1: craniotomy for tumor removal 10 6 3 x 10 9 3 mos 2: whole-brain radiation (6280 rads) 3: BCNU, procarbazine * LAK ceils = lymphokine-activated killer cells: IUDR = iododeoxyuridine; CCNU = 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea; BCNU =
1.3-bis(2-chloroethyl)-1 -nitrosourea.
Trial Design
Recombinant IL-2 or autologous LAK cells were injected intracerebrally at the time of craniotomy for tumor removal. Four patients were given IL-2 and five patients received LAK cells. Patient profiles including the dose and type of therapy administered are shown in Table 1 .
Interleukin-2 and Generation of LAK Cells
The method of purification and titration of purified recombinant IL-2* has been described previously) 3 This IL-2 at specific activities of approximately 10 6 U/ ml and IL-2 from Lot LP 232 and Lot LP 260 were used for these studies. The LAK cells used for injection were generated from peripheral blood lymphocytes (PBL) of the glioma patients as follows. Two to 3 days prior to surgery for tumor removal, blood was withdrawn from a peripheral vein. The PBL were then separated from other leukocytes by Ficoll-Hypaque gradient centrifugation according to methods described previously: The PBL were washed three times with Hanks' balanced salt solution (HBSS) and then resuspended in complete medium consisting of RPMI 1640 medium containing 5% human AB serum (heat-inac-* IL-2 was generously provided by Cetus Corp., Emeryville, California. tivated), 300 ug/ml of glutamine, 100 gm/ml penicillin, and 100 mg/ml streptomycin.t The PBL were activated to generate LAK cells by in vitro incubation for 2 days in media containing 100 Cetus units of IL-2/ml. The PBL from Cases 3, 4, 7, and 8 were cultured in 175-cc flasks in 50 cc of complete medium at a concentration of 1 x 106 cells/ml. Due to the large number of cells involved, PBL from Cases 9 and 10 were cultured in 175-cc flasks in 175 ml of complete medium at a concentration of 2.5 x 10 6 cells/ml. The flasks were incubated upright in 5% CO2 at 37~
Three patients (Cases 8, 9, and 10) were treated with over 1 x 108 LAK cells. In order to obtain this large number of PBL, these patients underwent lymphocytopheresis at the NIH Apheresis Unit which uses the IBM 2997 continuous-flow cell separator. 6 After the 2-to 3-day incubation period, the cells were washed three times in HBSS and resuspended in a final volume of 5 cc of HBSS for intracerebral injection. An aliquot of these LAK cells was cryopreserved and subsequently thawed when used as effector cells in the microcytotoxt Hanks' balanced salt solution manufactured by Gibco Laboratories, Grand Island Biological Co., Grand Island, New York; RPMI 1640 medium manufactured by Advanced Biotechnologies, Inc., Silver Spring, Maryland; and glutamine, penicillin, and streptomycin manufactured by Biofluide Inc., Rockville, Maryland. icity assay as described below. In addition, PBL that were not cultured with IL-2 were also cryopreserved and used as effector cells.
Injection of lL-2 or LAK Cells
The IL-2 or LAK cells were injected directly into the brain tissue surrounding the cavity left by operative tumor debulking. The cells were suspended in 5 to 15 cc of HBSS, and administered through a No. 20 blunt brain cannula via multiple intracerebral injections (five to eight, depending on the size of the tumor) distributed evenly around the resection cavity. The LAK cell or IL-2 suspension was injected at a rate of approximately 1 cc/min. Prior to injection, an aliquot of the LAK cell suspension was sent for Gram-stain analysis and culture.
Pretreatment and Follow-Up Investigations
Baseline studies included history and physical examination, a Karnovsky performance test, CT scanning with contrast medium, a complete blood count (CBC) with differential WBC count, a biochemical profile including electrolytes, serum creatinine, calcium, magnesium, and uric acid, a chest radiograph, and an electrocardiogram. During the 7-to 10-day postoperative period, patients underwent monitoring of vital signs every 1 to 4 hours, daily neurological examination, and assessment of serum electrolytes and CBC every 2 to 3 days. Prior to discharge 7 to 10 days following treatment, all patients had a CT scan with contrast enhancement. Patients were then seen either in the outpatient clinic at the NIH or by a neurologist in their home town every 6 to 8 weeks for assessment of neurological status. Patients were particularly monitored for signs and symptoms of toxicity, including fever, chills, lethargy, malaise, skin reaction, weakness, nausea, diarrhea, urinary frequency, urgency, hematuria, and incontinence.
Immunological Testing of LAK Cells
A chromium-release microcytotoxicity assay was utilized to test the ability of LAK cells administered to patients to lyse autologous and allogeneic glioma. At the time of in vitro testing, the LAK cells and PBL that had been previously cryopreserved were thawed and used as effector cells. Target cells included autologous fresh glioma (if available), autologous glioma grown in tissue culture (if available), allogeneic tissue culture glioma, and allogeneic PBL. The malignant and glial properties of tissue culture tumor lines established from fresh brain-tumor specimens in our laboratory have been confirmed by ultrastructural, 2~ biochemical, ~ and biophysical '7 techniques. The tissue culture lines were maintained 7 and the chromium-release microcytotoxicity assay was performed 4 as described previously. Single-cell suspensions of fresh glioma were prepared according to the modification of Shapiro's methods ~6 as reported previously. 7 Briefly, tumor tissue was minced The percentage of specific lysis in the chromiumrelease assay was calculated by the formula:
experimental epm -spontaneous epm maximal cpm -spontaneous cpm x 100% " All determinations were made in triplicate and data are reported as the mean + standard error of the mean.
Results
Intracerebral injections of LAK cells or IL-2 seemed to be well tolerated. Only one of the 10 treated patients (Case 3) who received 8 x 107 LAK cells became febrile transiently following treatment (Table 2 ). There were no associated signs of infection in this patient and the fever responded to Tylenol (acetaminophen) treatment. The WBC counts of Case 1 (treated with 104 U of IL-2) and Case 4 (treated with 108 LAK cells) markedly increased posttreatment without any associated signs or symptoms (Table 3) . Other than this, the patients' CBC and electrolyte patterns were unremarkable. Furthermore, malaise, skin reactions associated with allergic responses, or other adverse effects were not observed.
Contrast-enhanced CT scans were obtained from all patients before and 7 to 10 days after treatment. Representative scans from patients receiving IL-2 or LAK cells are shown in Figs. 1 and 2 , respectively. It can be seen that the posttreatment scans are not dissimilar from scans obtained following uncomplicated craniotomy for tumor removal, suggesting that intracerebral injection of IL-2 or LAK cells does not cause focal brain injury that can be detected radiographically.
One patient (Case 6) died from CT-demonstrated progressive tumor growth 9 weeks following operative tumor removal and injection of IL-2. Compared to their pretreatment status, the neurological status of eight of the remaining nine patients has either remained the same or improved slightly. Our first patient (Case 1) developed a left-sided hemisensory neglect which was apparent on the 1st postoperative day. A CT scan at that time demonstrated that this focal deficit was secondary to a stroke involving the right posterior thalamus (Fig. 3) . This stroke most likely resulted from sacrifice of a small feeding vessel in the course of removing a deep temporal lobe lesion. At his 10-month follow-up examination, this patient's deficit has not significantly improved. Another patient (Case 4) became moderately lethargic on the 1 st postoperative day, and a CT scan at that time demonstrated pneumocephalus. The pneumocephaly resolved and the patient became fully alert 24 hours after being ventilated with 100% 02.
Patient lymphocytes cultured without IL-2 did not lyse autologous or allogeneic glioma (Table 4) . However, when these cells were cultured with IL-2, LAK cells were generated which produced significant lysis of autologous glioma (in all of three cases) and allogeneic glioma (in five of seven cases). These LAK cells did not lyse normal PBL.
Discussion
We have previously reported that LAK cells generated by culturing brain-tumor patients' PBL with IL-2 produced marked selective lysis of autologous glioma cells] Preliminary results from the first 10 patients treated in our Phase I study suggest that IL-2 or autologous LAK cells can be safely administered intracere- * CBC = complete blood count; WBC = white blood cell count; RBC = red blood cell count; BUN = blood urea nitrogen; NT = not tested.
+ Day 0 represents the day on which patients underwent surgical tumor removal and administration of lymphokine-activated killer cells and/ or intedeukin-2.
brally to patients with malignant glioma. This represents the first report of the use of IL-2 or IL-2-activated lymphocytes in the treatment of h u m a n brain tumors. The tumor-selective cytotoxicity of injected L A K cells was verified by their ability to kill glioma in a chromium-release microcytotoxicity assay.
In experimental models, Rosenberg's group 1~ ~'~5 has shown that systemic administration of recombinant IL-2 and lymphocytes activated by IL-2 produced regression of established p u l m o n a r y metastases. Subse- to mild anemia (in all 23 patients), thrombocytopenia (in eight), and marked reversible eosinophilia (in 13). Pronounced weight gain (greater than 2 kg) occurred in 14 patients and was thought to be secondary to extravascular fluid accumulation.
In our study, the intracerebral administration of IL-2 did not appear to be associated with toxicity. The WBC count of our first patient (Case 1) dramatically rose following surgery and administration of the lowest dose of IL-2 (104 U). We believe that this was more likely a response to operative stress in a 69-year-old patient than to IL-2, since the WBC count of patients receiving higher doses of IL-2 remained stable following treatment. Furthermore, a marked transient increase of the WBC count occurred in one patient (Case 4) who received LAK cells but no IL-2. The apparent lack of fever or other toxicity following IL-2 administration in our study compared to that of Lotze, et al., 9 is almost certainly related to the fact that equivalent doses of IL-2 were given by direct intracerebral injection rather than intravenously. Most likely, intracerebral injection of IL-2 does not result in serum levels sufficient to produce systemic toxicity.
Glioblastoma cells have been shown to release a factor inhibiting IL-2-mediated induction of cytotoxic T cells, 2 and our own studies have shown that LAK cell activation is depressed in the presence of glioma cells in vitro. 3 Thus, our method of activating LAK cells in vitro in the absence of glioma, followed by local administration to the brain-tumor site, appears advantageous. In the present study, up to 10 ~~ autologous LAK cells have been administered by intracerebral injection without signs of toxicity. Of the five patients who received LAK cells, one patient (Case 3) was febrile for 2 days following treatment. We believe that this was unlikely to be an effect of the LAK cells, as this patient was mildly febrile with nasal congestion immediately prior to surgery and treatment with LAK cells. To date, there are only two other reports 12' 14 of the use of LAK cells activated with IL-2 in the treatment of human cancer. Initially, Rosenberg 12 reported that four patients with tumor involving the lung and liver tolerated intravenous infusion of large numbers of LAK cells. Specific data regarding toxicity were not given. More recently, 25 patients were studied and evidence was presented of significant toxicity. 14 Young, et al., 2~ have reported treating 17 patients with glioblastoma by injection of l0 7 to 10 9 autologous leukocytes. In contrast to our study, the cells administered by Young, et aL, were not activated in vitro prior to injection. Their finding that eight of 17 patients improved clinically and were alive 17 months posttreatment suggests that an even more marked effect is attainable following infusion of activated lymphocytes. In their study, the leukocytes were inoculated directly into the glioblastoma via indwelling catheters attached to a Rickham reservoir or by direct intratumoral injection through craniotomy sites using CT scan localization. Their only significant complication with this method occurred in one patient who developed Klebsiella meningitis. The intracerebral route used in our study and by Young, et al., 21 would be most likely to maximize cell-to-cell contact between killer lymphocytes and residual glioma cells. Furthermore, if injections are made into brain tissue grossly uninvolved with tumor, a relatively uncompromised blood-brain barrier may keep LAK cells localized to the injection site. To confirm that LAK cells remain in the local area, we have used autoradiography to study the fate of indium-11 l-labeled LAK cells injected directly into rat brains. We found that, at 48 hours after injection, 95% of LAK cells remained localized to the injection site (unpublished data, 1984) .
Conclusions
Our results demonstrate that the initial patients treated as part of our Phase I study have tolerated intracerebral infusions of IL-2 or LAK cells without signs of toxicity. These preliminary findings have justified continuation with the potentially therapeutic part of our Phase I trial, in which glioma patients will be treated in the same manner as our Case 10 (that is, with LAK cells and IL-2 delivered simultaneously).
